Search
May 20, 2024
ATS2024: Gossamer Bio presented open label extension data for seralutinib, an inhibitor of PDGFR, CSF1R, and c-KIT, in PAH showing durability of effect at 72 weeks
CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but...